Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ecadotril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME known ✓ | P08473 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 1/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 1/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 1/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.73 |
| ▸ | ECE1 | P42892 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexecadotril SCHEMBL1649041 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| Racecadotril SCHEMBL373243 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| Racecadotril SCHEMBL16098141 | 0.99 | CYP1A2 (0.98) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| Dexecadotril SCHEMBL28209442 | 0.94 | CYP1A2 (0.88) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10955802 | 0.94 | PPARA (0.88) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| Racecadotril SCHEMBL16098344 | 0.91 | CYP1A2 (0.82) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8165601 | 0.89 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10956150 | 0.89 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10952774 | 0.87 | CYP1A2 (0.78) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10956142 | 0.87 | CYP1A2 (0.77) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2865 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| WO-2024133913-A9 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2025-03-20 | — | — | WO | claimed |
| WO-2024133913-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| CN-117797061-B | An antiaging composition containing boscalin, ecadotine and ergothioneine | 广东万禧生物科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117797061-A | An antiaging composition containing boscalin, ecadotine and ergothioneine | 广东万禧生物科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-116603014-A | Formula and preparation method of antibacterial paste for treating acne pigment spot and skin-whitening | 王兴刚 | 2023-08-18 | — | — | CN | claimed |
| EP-3503926-B1 | NEW IMPROVED COMPOSITION OF RACECADOTRIL | JOHNSON & JOHNSON CONSUMER INC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022265697-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development, LLC (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220370360-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | ACCESS TO ADVANCED HEALTH INSTITUTE | 2022-11-24 | — | — | US | claimed |
| US-20210401751-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development Inc. (US) | 2021-12-30 | — | — | US | claimed |
| US-20040192584-A1 | Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor | PHARMACIA CORPORATION | 2004-09-30 | — | — | US | claimed |
| WO-2004082636-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A NEUTRAL ENDOPEPTIDASE INHIBITOR | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2003099279-A1 | COMBINATION OF A DPP IV INHIBITOR AND A CARDIOVASCULAR COMPOUND | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-20020028248-A1 | RAPID-RELEASE MICRODISPERSIBLE ECADOTRIL PREPARATION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-07 | — | — | US | claimed |
| EP-0820439-B1 | METHOD FOR THE ASYMMETRICAL SYNTHESIS OF S-ACYLATED DERIVATIVES OF 2-MERCAPTOMETHYL 3-PHENYL PROPANOIC ACID, AND USE THEREOF FOR SYNTHESISING N-(MERCAPTOACYL) AMINO ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2000-05-03 | — | — | EP | claimed |
| US-6013829-A | REDUCING A MALONIC DIESTER, HYDRIDING TO OBTAIN A DIOL, ACETYLATING TO OBTAIN A MONOESTER, OXIDATION, SAPONIFICATION AND THIOACYLATING; ENZYME INHIBITORS; PROTEASES; OPTICS; ANTISECRETORY AND HYPOTENSIVE AGENTS | SOCIETE CIVILE BIOPROJET (FR) | 2000-01-11 | — | — | US | claimed |
| EP-0729936-B1 | Process for the synthesis of alpha substituted acrylic acids and N-(mercaptoacyl)amino acids | BIOPROJET SOC CIV (FR) | 1999-07-07 | — | — | EP | claimed |
| EP-0914822-A1 | RAPID-RELEASE MICRODISPERSIBLE ECADOTRIL PREPARATION | Bayer Aktiengesellschaft (DE) | 1999-05-12 | — | — | EP | claimed |
| WO-1993011797-A1 | DRUG CONTAINING AN ATRIOPEPTIDASE INHIBITOR AND AT LEAST ONE CALCIC ANTAGONIST | SOCIETE CIVILE BIOPROJET (FR) | 1993-06-24 | — | — | WO | claimed |